We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

150 hedge funds and large institutions have $334M invested in Akebia Therapeutics in 2019 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 44 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,023% more call options, than puts

Call options by funds: $19.3M | Put options by funds: $468K

0% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 44

1% less funds holding

Funds holding: 151 → 150 (-1)

5% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 21

2.05% less ownership

Funds ownership: 73.76% → 71.7% (-2.1%)

21% less capital invested

Capital invested by funds: $421M → $334M (-$86.5M)

Holders
150
Holders Change
-1
Holders Change %
-0.66%
% of All Funds
3.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
44
Reduced
44
Closed
21
Calls
$19.3M
Puts
$468K
Net Calls
+$18.8M
Net Calls Change
-$4.86M

Top Buyers

1
SI
Sofinnova Investments
California
+$1.62M
2
BlackRock
BlackRock
New York
+$1.51M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.27M
4
Northern Trust
Northern Trust
Illinois
+$1.21M
5
Citadel Advisors
Citadel Advisors
Florida
+$1.15M

Top Sellers

1
State Street
State Street
Massachusetts
-$9.23M
2
Man Group
Man Group
United Kingdom
-$2.44M
3
OWIM
Old West Investment Management
California
-$935K
4
Morgan Stanley
Morgan Stanley
New York
-$809K
5
Bank of America
Bank of America
North Carolina
-$785K
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
1
Baupost Group
Massachusetts
$95.9M – – –
BlackRock
2
BlackRock
New York
$41.5M +$1.51M +352,730 +3%
NCM
3
Nantahala Capital Management
Connecticut
$22.7M – – –
ACM
4
Abrams Capital Management
Massachusetts
$22.2M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$21.4M +$1.27M +296,126 +6%
State Street
6
State Street
Massachusetts
$14.3M -$9.23M -2,153,025 -37%
NHAS
7
Novo Holdings A/S
Denmark
$12.2M – – –
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$6.95M +$638K +148,900 +9%
N
9
Nuveen
North Carolina
$6.72M +$362K +84,478 +5%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$6.19M +$342K +79,729 +5%
RHJA
11
Rice Hall James & Associates
California
$5.82M -$42.6K -9,933 -0.7%
Northern Trust
12
Northern Trust
Illinois
$5.62M +$1.21M +282,258 +24%
ClearBridge Investments
13
ClearBridge Investments
New York
$4.97M -$521K -121,549 -9%
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$4.92M +$874K +203,888 +19%
SI
15
Sofinnova Investments
California
$4.81M +$1.62M +378,835 +45%
Morgan Stanley
16
Morgan Stanley
New York
$4M -$809K -188,721 -16%
Norges Bank
17
Norges Bank
Norway
$3.61M – – –
DCM
18
DAFNA Capital Management
California
$3.25M -$10.7K -2,500 -0.3%
Charles Schwab
19
Charles Schwab
California
$2.75M +$228K +53,303 +8%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$2.62M -$18.5K -4,317 -0.6%
PIMJS
21
PKO Investment Management Joint-Stock
Poland
$2.15M – – –
AG
22
Artal Group
Luxembourg
$1.67M – – –
D.E. Shaw & Co
23
D.E. Shaw & Co
New York
$1.6M -$504K -117,549 -22%
Wellington Management Group
24
Wellington Management Group
Massachusetts
$1.57M -$43.1K -10,065 -2%
Citadel Advisors
25
Citadel Advisors
Florida
$1.45M +$1.15M +268,218 +262%
1
2 3 4 5

AKBA Hedge Fund Activity: Q3 2019 in Review

150 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2019, worth a combined $334M — down 21% from $421M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of AKBA and 20 opened new positions — a net loss of 1 holder — while 44 trimmed existing stakes and 44 added.

The largest buyer was Sofinnova Investments, adding an estimated $1.62M. The largest seller was State Street, cutting an estimated $9.23M.

  • 150 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2019, down from 151 in Q2 2019.
  • Funds reported $334M of Akebia Therapeutics stock for Q3 2019, down 21% quarter-over-quarter.
  • 20 funds opened new Akebia Therapeutics positions in Q3 2019 and 21 closed out, a net change of -1 holder.
  • The largest Akebia Therapeutics buyer in Q3 2019 was Sofinnova Investments, an estimated $1.62M added.
  • The largest Akebia Therapeutics seller in Q3 2019 was State Street, an estimated $9.23M sold.

Based on aggregated 13F filings for Q3 2019.